Welcome to the 3rd Cannabinoid Derived Pharmaceuticals Summit
In a year that saw a significant rise in the clinical pipeline of cannabis-derived therapeutics and the worldwide sales of Epidiolex soar, the 3rd International Cannabinoid Derived Pharmaceuticals Summit is back to facilitate continued growth in this sector and set the tone for the next year of forecasted groundbreaking research.
With over 20+ hours of content, 2 streams, a workshop day featuring 4 interactive sessions, and 5+ hours of networking, you can join the only platform discussing issues present in the development and commercialization of pharmaceuticals with cannabinoids as an API.
Join this critical global forum which will again be uniting industry specialists from pharma, biotechs, academia and solution providers as we target the most pressing issues important to bringing the next generation of CDPs to market.
Our 2020 Expert Speakers Included:
Boaz Hirshberg
Executive Vice President, Chief Medical Officer, Head of Global Development
BOL Pharma
Pavel Pachta
Director for International Regulatory Affairs
International Cannabis and Cannabinoids Institute (ICCI)
Hear From Some Previous iCDP Attendees:
- “How about one word? Fantastic” - Jeff Margolis, RespireRx Pharmaceuticals Inc.
- “Inspiring to be in the presence of many cannabinoid experts who all share the same passion for cannabinoid science” – Emma Lennon, GW Pharmaceuticals
- “World class talent from biotech and cannabis research converged to shape the future of an emerging industry – Cannabinoid Medicines” – Andrea Small-Howard, GBS Global Biopharma
- “Amazing information presented and top quality contacts for networking” – Ted Reynolds, FlackTek Inc.
2020 Partners Included:
Other Events in the Series
